Compounds > adenosine monophosphate
Page last updated: 2024-08-17

adenosine monophosphate and Shock, Cardiogenic

adenosine monophosphate has been researched along with Shock, Cardiogenic in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19901 (9.09)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (63.64)24.3611
2020's3 (27.27)2.80

Authors

AuthorsStudies
Canonico, ME; Parodi, G; Saba, PS; Siciliano, R; Talanas, G1
Clement, KC; Isani, M; Kihlstrom, M; McLean, SE; Phillips, MR; Schwartz, SP; Smith, MM; Smith, RL; Walker, TC1
Altshuler, D; Arnouk, S; Katz, A; Lewis, TC; Merchan, C; Papadopoulos, J; Smith, DE; Toy, B1
Bhatt, DL; Borst, O; Droppa, M; Gawaz, M; Geisler, T; Müller, K; Rath, D1
Badreldin, HA; Bhatt, DL; Faxon, DP; Qamar, A; Vaduganathan, M2
Moliterno, DJ1
Lozano, I; Rondan, J; Segovia, E; Vegas, JM1
DeVore, AD; Milano, CA; Patel, CB; Washam, JB; Welsby, IJ; Yerokun, B1
Bhatt, DL; de Waha-Thiele, S; Desch, S; Droppa, M; Fuernau, G; Gawaz, M; Geisler, T; Hack, L; Jaffer, FA; Ouarrak, T; Qamar, A; Rath, D; Roberts, RJ; Schneider, S; Singh, A; Szumita, PM; Thiele, H; Vaduganathan, M; Venkateswaran, RV; Zeymer, U1
Kloppick, E; Krause, EG; Schneider, M; Vogel, I; Wollenberger, A1

Trials

1 trial(s) available for adenosine monophosphate and Shock, Cardiogenic

ArticleYear
Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
    Resuscitation, 2019, Volume: 137

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Combined Modality Therapy; Female; Humans; Male; Matched-Pair Analysis; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Shock, Cardiogenic

2019

Other Studies

10 other study(ies) available for adenosine monophosphate and Shock, Cardiogenic

ArticleYear
Cangrelor-supported primary percutaneous coronary intervention in a patient with cardiogenic shock due to left main acute occlusion.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:8

    Topics: Adenosine Monophosphate; Coronary Occlusion; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Treatment Outcome

2020
Extracorporeal Membrane Oxygenation for COVID-19-Associated Multisystem Inflammatory Syndrome in a 5-year-old.
    The American surgeon, 2022, Volume: 88, Issue:2

    Topics: Adenosine Monophosphate; Adrenergic alpha-Agonists; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Child, Preschool; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Epinephrine; Extracorporeal Membrane Oxygenation; Female; Humans; Hypotension; Immunization, Passive; Immunoglobulins, Intravenous; Interleukin 1 Receptor Antagonist Protein; Methylprednisolone; Norepinephrine; Shock, Cardiogenic; Systemic Inflammatory Response Syndrome

2022
Clinical Use of Cangrelor After Percutaneous Coronary Intervention in Patients Requiring Mechanical Circulatory Support.
    The Annals of pharmacotherapy, 2021, Volume: 55, Issue:10

    Topics: Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Retrospective Studies; Shock, Cardiogenic

2021
Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 42, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Aged; Cardiotonic Agents; Female; Gene Expression; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y; Shock, Cardiogenic; Survival Analysis

2017
Cangrelor Use in Cardiogenic Shock: A Single-Center Real-World Experience.
    JACC. Cardiovascular interventions, 2017, 08-28, Volume: 10, Issue:16

    Topics: Adenosine Monophosphate; Humans; Shock, Cardiogenic; Stents; Treatment Outcome

2017
Research Correspondence: One Good Point, One Great Figure (or Table).
    JACC. Cardiovascular interventions, 2017, 11-27, Volume: 10, Issue:22

    Topics: Adenosine Monophosphate; Humans; Shock, Cardiogenic; Treatment Outcome

2017
Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock.
    JACC. Cardiovascular interventions, 2017, 12-11, Volume: 10, Issue:23

    Topics: Abciximab; Adenosine Monophosphate; Humans; Immunoglobulin Fab Fragments; Shock, Cardiogenic

2017
Cangrelor or Abciximab as First Choice in Cardiogenic Shock.
    JACC. Cardiovascular interventions, 2017, 12-11, Volume: 10, Issue:23

    Topics: Abciximab; Adenosine Monophosphate; Humans; Immunoglobulin Fab Fragments; Shock, Cardiogenic

2017
Cangrelor use prior to left ventricular assist device surgery: a case series.
    Journal of thrombosis and thrombolysis, 2018, Volume: 46, Issue:2

    Topics: Adenosine Monophosphate; Aged; Cardiovascular Surgical Procedures; Female; Heart Ventricles; Heart-Assist Devices; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Shock, Cardiogenic

2018
[Effect of intra-aortic balloon counterpulsation on the hemodynamics and the metabolism of the non-ischemic and ischemic left heart ventricle].
    Zeitschrift fur experimentelle Chirurgie, 1973, Volume: 6, Issue:5

    Topics: Adenosine Monophosphate; Adenosine Triphosphate; Animals; Assisted Circulation; Blood Pressure; Disease Models, Animal; Dogs; Heart; Heart Ventricles; Hemodynamics; Lactates; Ligation; Myocardial Infarction; Myocardium; Shock, Cardiogenic

1973